The family of growth factors that includes epidermal growth factor (EGF) and transforming growth factor-a (TGF-a) are thought to play a role in the regulation of fetal lung development and epithelial repair after injury. To further elucidate the potential role of these growth factors and their receptor in normal human lung development and in response to injury, their distribution was determined by immunohistochemistry in normal fetal lung, as well as both normal and injured postnatal human lung. We studied 14 specimens of human lung tissue: from three fetuses, four normal infants, two preterm infants with hyaline membrane disease, and five infants with late bronchopulmonary dysplasia (BPD). EGF, TGF-a, and EGF receptor (EGF-R) colocalized in airway epithelium in normal fetal and in postnatal human lung. They were also colocalized in scattered alveolar epithelial cells in postnatal lung. Large numbers of alveolar macrophages immunostained for EGF, TGF-a, and EGF-R in lungs with late stages of BPD. The colocalization of these growth factors suggests parallel expression of EGF family members. Moreover, the colocalization of these growth factors with their receptor in developing lung suggests that they may act through an autocrine mechanism. The prominent expression of these growth factors in alveolar macrophages in BPD suggests they may be involved with the pathogenesis of this disease. (Pediatr Res 38: 851-856,1995) Abbreviations BPD, bronchopulmonary dysplasia EGF, epidermal growth factor EGF-R, epidermal growth factor receptor HMD, hyaline membrane disease TGF-a, transforming growth factor-a EGF and TGF-a are members of a family of proteins, the EGF family, which act through binding the EGF-R (1, 2).
Human TGF-a and EGF share 42% sequence homology (3, 4) and have similar biologic activities in vitro. They are capable of stimulating proliferation of epithelial cells, endothelial cells, smooth muscle cells, and fibroblasts (5) . Members of the EGF family have also been shown to be potent stimulants of the migration of many cell types, including keratinocytes, liver epithelial cells, enterocytes, corneal cells, and endothelial cells (6) (7) (8) (9) (10) . These properties have led to the speculation that members of the EGF family may be involved in the regulation of developmental processes.
Indeed, there is considerable evidence that members of the EGF family play a significant role in both normal lung development and response to injury. EGF-R have been identified in fetal mouse and rabbit lung and on rat type I1 pneumocytes (1 1-13). EGF immunoreactivity has been localized in epithelial cells, mesenchymal cells, and extracellular matrix of fetal mouse lung at 11 d of gestation (14) . EGF has been shown, by immunohistochemistry, to be present in normal human fetal tracheal and bronchial submucosal glands and airway epithelial cells (15) , but not in bronchiolar or alveolar cells. TGF-a mRNA has been isolated from human fetal lung during the pseudoglandular and canalicular stages. TGF-a immunoreactivity has been localized predominantly in epithelial cells, but it was also present in vascular smooth muscle and scattered mesenchymal cells (16). TGF-a mRNA has been isolated from late gestation rat lung (17, 18). EGF and TGF-a immunoreactivity have been colocalized with EGF-R in fetal rat lung epithelial cells (1 9).
STRANDJORD ET AL.
Stimulation of EGF-R activity in developing lung has been shown to promote growth and differentiation. Goldin and Opperman (20) demonstrated that agarose beads containing EGF can stimulate the formation of supernumerary tracheal buds from chick embryo foregut in much the same manner as the grafting of mesodermal tissue. Warburton et al. (14) have shown that treatment of fetal mouse lung organ explants with exogenous EGF stimulates branching morphogenesis and cellular proliferation and that specific inhibition of EGF-R function inhibits branching morphogenesis and cellular proliferation (14) . Also, inhibition of endogenous EGF production with an antisense oligonucleotide directed against EGF in fetal mouse lung explants reduced airway branching (21) . Pharmacologic treatment of fetal rat, monkey, rabbit, and sheep lungs at various gestational ages with EGF results in accelerated type I1 cell differentiation, DNA synthesis, and surfactant production (22) (23) (24) (25) .
There is also evidence that the EGF family may play a role in the response of lung to injury. Fibroblasts isolated from lungs of hamsters exposed to hyperoxia secreted TGF-a, whereas fibroblasts from normal lungs did not (26) . In a rat model of lung injury, lungs exposed to bleomycin had increased steady state levels of TGF-a and EGF-R mRNA, increased TGF-a protein content, and increased EGF-R (27) . These findings suggest that the local release of TGF-a may influence the lung's response to injury.
To better understand the role of EGF family growth factors in normal human lung development we have immunolocalized EGF, TGF-a, and EGF-R in developing human fetal and infant lung. We have also studied the distribution of EGF, TGF-a, and EGF-R in injured lung from infants with HMD and BPD as a first step in analyzing the role of these growth factors in the response of infant lung to injury.
METHODS
Tissue specimens. This study was approved by the Institutional Review Committee of the University Washington School of Medicine. Fetal lung tissue samples from three therapeutically aborted fetuses at 11, 17, and 20 wk of gestation (obstetrical dates used throughout, computed by adding 2 wk to postconceptional age) with no known congenital abnormalities were collected by the Central Laboratory for Human Embryology of the University of Washington. Gestational age was estimated by foot length (28) . All tissue was fixed in 10% buffered formalin within 30 min of abortion.
Normal infant lung tissue samples from four infants at 3, 6, 9, and 12 mo of age were obtained from the King County Medical Examiners Office, Seattle, WA. The 3-mo-old infant was diagnosed with sudden infant death syndrome. All other infants expired in motor vehicle accidents. None of these infants had any known pulmonary abnormalities. All tissue was fixed in 10% buffered formalin.
Lung tissue samples from two infants with severe early HMD and five infants with BPD were obtained from the pathology service of the University of Washington Medical Center, Seattle, WA. The infants diagnosed with severe early HMD were 24 and 25 wk of gestation with birth weights 568 and 750 g, respectively, and died in the 1st d of life. The diagnosis of HMD was based on a clinical course and chest roentgenograms consistent with the disease, as well as typical pathologic changes, which included the presence of hyaline membranes and widespread atelectasis. The infants diagnosed with BPD were 23.5-31 wk of gestation, with birth weights ranging 680-1453 g, and died of respiratory failure at 34-151 d of age. The diagnosis of BPD was based on a clinical course and chest roentgenograms consistent with the disease (29) , as well as typical pathologic changes, which included extensive fibrosis and alternating areas of atelectasis and emphysema. All tissue was fixed in 10% buffered formalin.
Antibodies. An affinity-purified mouse monoclonal IgG,,, antibody to human recombinant TGF-a (Oncogene Science, Manhasset, NY) was used to detect TGF-a (16, 30, 31). It recognizes an epitope within the carboxyl-terminal 17-amino acid residues of TGF-a (residues 34-50) and does not cross-react with EGF. EGF-R was detected using an affinity-purified rabbit polyclonal IgG antibody (Oncogene Science) raised against the peptide (DVVDADEYLIPQ) that corresponds to amino acid residues 1005-1016 of the cytoplasmic domain of the human EGF-R (32). This antibody specifically reacts with the 170-kD EGF-R protein by irnrnunoblot analysis (manufacturer's specifications). An affinity-purified rabbit polyclonal IgG antibody to human recombinant EGF (Oncogene Science) was used to detect EGF. Epithelial cells were specifically stained with a mouse monoclonal antihuman cytokeratin, clones AE1 and AE3 (Boehringer Mannheim, Indianapolis, IN) (33) . HAM-56, a mouse MAb specific for macrophages (Dako Corporation, Carpinteria, CA), was used to identify alveolar macrophages (34) .
Zmmunohistochemistry. Sections of lung 5 p m thick were stained with the ABC peroxidase method as previously described (16, 35). The sections were counterstained with methyl green. Sections immunostained with anti-cytokeratin or HAM-56 antibodies were enhanced with nickel chloride and counterstained with acridine orange (36) . Color photomicrographs were produced using a Jenaval photomicroscope and Kodak Ektachrome 64T transparency film. The slides were scanned and digitized on a Kodak Photo CD. The digitized images were then processed using Adobe Photoshop for Windows 2.5 software (Adobe Systems Inc., Mountain View, CA) with identical parameters for all micrographs in each figure and were printed on a Phaser I1 SDX dye sublimation printer (Tektronix, Beaverton, OR). As a control for specificity of the TGF-a, EGF, and EGF-R antibodies, a 10-fold excess, by weight, of either human recombinant TGF-a (Life Technologies, Inc., Gaithersburg, MD), human recombinant EGF (Life Technologies), or the synthetic EGF-R peptide (DVVDADEYLIPQ, used to generate the EGF-R antibody) was used to preabsorb each of the antibodies at room temperature for 1 h. These preabsorbed antibody preparations were used to stain serial fetal lung tissue sections, as described above.
RESULTS
Normal lung. Serial tissue sections from fetal human lungs at 11, 17, and 20 wk of gestation, as well as from normal postnatal lungs from infants 3, 6, 9, and 12 mo of age (Table   1) were immunostained for TGF-a, EGF, and EGF-R (Fig. 1) . TGF-a, EGF, and EGF-R were colocalized in lungs at all ages studied ( Table 2 ). The two growth factors and their receptor were uniformly present in bronchial epithelium and submucosal glands, as well as in bronchiolar epithelium. Staining for TGF-a, EGF, and EGF-R was observed in alveolar epithelium and in vascular smooth muscle in normal postnatal lung. Scattered alveolar macrophages also were immunopositive for TGF-a, EGF, and EGF-R.
Lung with HMD and BPD. Serial tissue sections from lungs of premature infants, 23.5-31 wk of gestation, who died with HMD, at 1 d of age, and BPD, at 34-151 d of age (Table I) , were immunostained for TGF-a, EGF, and EGF-R, as well as for markers for alveolar macrophages and epithelial cells (Figs.  2 and 3) . As in normal lung, TGF-a, EGF, and EGF-R expression were colocalized ( Table 3 ). The two growth factors and their receptor were uniformly present in bronchial epithelium and submucosal glands, as well as in bronchiolar epithelium, throughout development and in spite of disease state. Staining for TGF-a, EGF, and EGF-R was also observed in alveolar epithelium and in vascular smooth muscle in older infants with BPD.
In contrast to normal lungs, alveolar macrophages were abundant in lungs of infants with BPD, as demonstrated by immunostaining with HAM56 antibody (Fig. 3 4 . Serial sections were also immunostained for TGF-a, EGF, and EGF-R (Fig. 3 and Table 2 ). Staining of intraalveolar macrophages with each of the antibodies in these sections suggested colocalization of these factors and their receptor in these cells. Intraalveolar macrophages were consistently immunostained for TGF-a, EGF, and EGF-R in all fields. (Fig. 4) . alone. This indicated that there was no cross-reactivity of these Imrnunoreactivity was not detected in the sections stained with antibodies with the other antigens studied. each antibody preabsorbed with its respective antigen, indicating that each antibody reacted with its soluble antigen. Also, the up to 1 y of age. These growth factors and their receptor were consistently present in bronchial epithelium and submucosal glands, as well as in bronchiolar epithelium in both normal and injured developing lung. In postnatal infants they were present in alveolar epithelium with variable intensity of immunostaining. EGF, TGF-a, and EGF-R were also present in fetal pulmonary vascular smooth muscle, but immunoreactivity was relatively less pronounced in postnatal infants. These results are consistent with descriptions of the distribution of TGF-a in fetal human and rat lung previously reported by our laboratory (16, 19) , as well as the localization of EGF and EGF-R in developing mouse and rat lung (13, 14, 19, (37) (38) (39) . EGF-R has been described in fetal rat (19) and mouse lung airways (14) and in adult rat type I1 alveolar epithelial cells in primary culture (13) . Normal fetal and infant human lung EGF (15) and EGF-R (40) have been previously identified in tracheal and bronchial epithelium as well as submucosal glands. In contrast we detected EGF and its receptor in lung epithelium at all levels. It is possible that the discrepancy between those reports and our own observations could be explained by differences in the antibodies used. The colocalization of TGF-a, EGF, and EGF-R in airway epithelium supports the hypothesis that EGF and TGF-a function in an autocrine manner to modulate epithelial cell function as has previously been suggested for EGF (13) . The identification of these growth factors and their receptor in human fetal and infant airways implicates these growth factors in regulation of human lung development. Their prominent localization in airway epithelium suggests a possible role in airway growth and epithelial cell differentiation and maturation. Many studies of pharmacologic treatment of developing lung with EGF have demonstrated potent effects on branching morphogenesis (14, 20, 21) and lung epithelial cell maturation (22) (23) (24) (25) . Taken together, these studies indicate that EGF can exert effects on both lung morphogenesis and functional maturation of epithelial cells. Inasmuch as TGF-a acts through the same receptor, it might be anticipated that TGF-a would have qualitatively similar effects.
SpeciJicity of immunohistochemistry. Specificity of the EGF, TGF-a, and EGF-R antibodies was
The coimmunolocalization of TGF-a and EGF in developing human lung also suggests that these growth factors may have similar effects in lung development. The simultaneous presence of TGF-a and EGF in fetal lung could explain the inability to inhibit fetal lung growth by the administration of anti-EGF antibody to pregnant mice, despite the elimination of detectible EGF from fetal serum (41) . Likewise, normal lung development reported in TGF-a deficient transgenic mice could be due to the presence of EGF during pulmonary organogenesis (42, 43) . However, the ability of antisense oligonucleotide directed against EGF to inhibit lung growth in cultured mouse embryo lungs at 11 d of gestation argues against precisely overlapping functions for TGF-a and EGF in lung morphogenesis (21) . It is possible, for example, that local differences in the microenvironment might favor the function of one EGF family member over another.
In lung damaged by HMD the pattern of EGF, TGF-a, and EGF-R expression was similar to that seen in fetal lung, except for the expected disruption of distal airway epithelium. Given the potent effects of EGF on developing lung it is possible that the disruption of expression these growth factors in damaged epithelium could contribute to the pathogenesis of abnormal lung growth seen after injury.
The most distinctive histologic feature of lungs from infants with BPD was the abundance of alveolar macrophages that were immunopositive for TGF-a, EGF, and EGF-R. This finding is consistent with a previous report of immunolocalization of TGF-a and EGF-R in alveolar macrophages of injured rat lung (27) . In addition, it has been shown that human alveolar macrophages produce TGF-a, when stimulated with IRD ET AL. endotoxin (44) . The association of the EGF family of growth factors with alveolar macrophages suggests that they may be involved with the fibroproliferative changes seen in BPD. Transgenic mice that overexpress the human TGF-a gene under the regulatory control of human surfactant C promoter develop pulmonary fibrosis with fibrotic lesions localized in peribronchial, peribronchiolar, and perivascular regions (45). The actions of these growth factors in BPD remains uncertain. Their mitogenic (46-48), chemotactic (6-lo), and fibrosisstimulating properties, however, could play a significant role in the pathogenesis of abnormal lung growth and fibrosis seen in this disease.
In summary, TGF-a, EGF, and the EGF-R are colocalized in fetal lung from midgestation and in infant lung up to 1 y of age. These growth factors and their receptor are present in airways of both normal and injured developing lung. In lungs from infants who died with BPD prominent immunostaining is seen in alveolar macrophages. These results suggest that the EGF family of growth factors may play a role in normal airway growth, as well as in the abnormal growth and fibrosis seen in BPD.
